Q-omics provides the consensus-scored SHC4 profile across patient tissues and cancer cell-line models. SHC4 expression is associated with patient survival in 29 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, SHC4 is differentially expressed in 9, with the highest sampling consensus in KICH. Additionally, SHC4 RNA expression shows 17,739 significant gene co-expression associations, with the highest sampling consensus in KIRP. Together, these results highlight KIRP, and KICH as cancer lineages where SHC4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SHC4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SHC4 survival associations across molecular data types. SHC4 RNA expression shows survival associations in the most cancer types (29), followed by mutation status (3) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SHC4 RNA expression–survival associations across cancer types. High SHC4 expression shows unfavorable associations in KIRP, KICH, STAD and LGG, but favorable associations in UVM and UCS. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .003). Together, the overview and detailed table identify KIRP as the clearest survival context for SHC4 RNA expression.
This table summarizes SHC4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in KICH for RNA.
This table ranks reproducible tumor–normal expression differences for SHC4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SHC4 shows lower tumor expression in KICH, BRCA, UCEC and PRAD and higher tumor expression in THCA and LIHC. The KICH box plot shows higher SHC4 RNA expression in normal versus tumor tissue (log2 FC = −0.517, t-test p < 0.001).
This table shows molecular features associated with SHC4 in patient tissues and cancer cell lines. In patient samples, SHC4 shows the broadest associations at the RNA and protein expression levels, with KIRP recurring as the lineage with the largest associated feature set. In cancer cell lines, SHC4 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and BLOOD_Leukemia.
